---
title: "Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286572943.md"
description: "Sutro Biopharma, Inc.'s stock price target has been raised from $35.73 to $41.64, indicating an 8% potential upside based on the May 14 closing price. The consensus rating remains a 'Buy' from 12 analysts, with 11 recommending 'Buy' and 1 'Sell'."
datetime: "2026-05-15T13:20:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286572943.md)
  - [en](https://longbridge.com/en/news/286572943.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286572943.md)
---

# Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside

-   According to estimates from 11 analysts, Sutro Biopharma, Inc. stock's average price target has risen from $35.73 to $41.64, with forecasts ranging from $9 to $60 per share
-   Based on the May 14 closing price, the updated target implies approximately 8% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 11 Buys, 0 Holds and 1 Sells

Explore more price target data and ratings for Sutro Biopharma, Inc. on the , and track all previous and future analyst recommendations for Sutro Biopharma, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [STRO.US](https://longbridge.com/en/quote/STRO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)